This study is in progress, not accepting new patients
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
Summary
- Eligibility
- for people ages up to 25 years (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Michelle Hermiston
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Michelle Hermiston
Associate Professor, Pediatrics, School of Medicine. Authored (or co-authored) 109 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT03610724
- Phase
- Phase 2 Research Study
- Study Type
- Interventional
- Participants
- At least 33 people participating
- Last Updated